Michael Gelband’s Dianthus Therapeutics DNTH Stock Holding History

Michael Gelband’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-85,530	Closed	-$7.18M	–	1674
2026 Q1	$7.18M	Sell	85,530 -161,258	-65%	-$9.34M	0.06%	326
2025 Q4	$10.2M	Buy	+246,788	New	+$9.57M	0.08%	256
2025 Q3	–	Sell	-75,079	Closed	-$1.4M	–	1654
2025 Q2	$1.4M	Buy	+75,079	New	+$1.41M	0.01%	861
2024 Q2	–	Sell	-16,996	Closed	-$510K	–	1623
2024 Q1	$510K	Buy	+16,996	New	+$369K	﹤0.01%	1133
2021 Q2	–	Sell	-1,210	Closed	-$229K	–	2454
2021 Q1	$229K	Buy	+1,210	New	+$204K	﹤0.01%	1821
2020 Q3	–	Sell	-2,736	Closed	-$329K	–	1848
2020 Q2	$329K	Buy	+2,736	New	+$385K	0.01%	1277

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Michael Gelband's DNTH Position: Q2 2026 in Review

Michael Gelband sold out of Dianthus Therapeutics (DNTH) in Q2 2026, closing a stake of 85,530 shares — an estimated $7.18M sold.

Michael Gelband first reported a position in DNTH in Q2 2020 and held it in 6 quarters. The position peaked at $10.2M in Q4 2025. 267 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Michael Gelband reported no remaining Dianthus Therapeutics position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 85,530 Dianthus Therapeutics shares in Q2 2026, an estimated $7.18M.
Michael Gelband first reported a position in Dianthus Therapeutics in Q2 2020 and held it in 6 quarters.
Michael Gelband's Dianthus Therapeutics position peaked at $10.2M in Q4 2025.
267 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.